Combined hormonal pills and thrombosis: From clinical data to media consequences;Contraception œstroprogestative et risque thrombotique: Des faits cliniques aux conséquences médiatiques

Revue de Medecine Interne

Volumn 34, Issue 8, 2013, Pages 453-455

  Levesque H ^a   Hanslik, T ^b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Combined hormonal pills; Deep vein thrombosis; Myocardial infarction; Pulmonary embolism; Stroke

Indexed keywords

CONTRACEPTIVE AGENT;

ARTICLE; DEEP VEIN THROMBOSIS; DRUG SURVEILLANCE PROGRAM; HUMAN; LUNG EMBOLISM; THROMBOSIS;

ACCIDENT VASCULAIRE CÉRÉBRAL; COMBINED HORMONAL PILLS; CONTRACEPTION ŒSTROPROGESTATIVE; DEEP VEIN THROMBOSIS; EMBOLIE PULMONAIRE; INFARCTUS; MYOCARDIAL INFARCTION; PULMONARY EMBOLISM; STROKE; THROMBOSE VEINEUSE PROFONDE;

ATTITUDE TO HEALTH; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; MASS MEDIA; PRACTICE GUIDELINES AS TOPIC; PUBLIC OPINION; RISK FACTORS; TABLETS; THROMBOSIS;

EID: 84881545448     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2013.04.019     Document Type: Article

References (19)

1. Plu-Bureau G., Maitrot-Mantelet L., Hugon-Rodin J., Canonico M. Hormonal contraceptives and venous thromboembolism: an epidemiological update. Best Pract Res Clin Endocrinol Metab 2013, 27:25-34.
2. Gourdy P., Bachelot A., Catteau-Jonard S., Chabbert-Buffet N., Christin-Maître S., Conard J., et al. Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology. Ann Endocrinol (Paris) 2012, 73:469-487.
3. Lidegaard Ø., Nielsen L.H., Skovlund C.W., Skjeldestad F.E., Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011, 343:d6423.
4. Gomes M.P., Deitcher S.R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004, 164:1965-1976.
5. Lévesque H., Borg J.Y., Courtois H. Risque vasculaire des pilules de troisième génération. J Mal Vasc 1997, 22:5-12.
6. Gaussem P., Alhenc-Gelas M., Thomas J.L., Bachelot-Loza C., Remones V., Ali F.D., et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost 2011, 105:560-567.
7. Vandenbroucke J.P., Koster T., Briët E., Reitsma P.H., Bertina R.M., Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994, 344:1453-1457.
8. Wu O., Robertson L., Langhorne P., Twaddle S., Lowe G.D., Clark P., et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005, 94:17-25.
9. Dayan N., Holcroft C.A., Tagalakis V. The risk of venous thrombosis, including cerebral vein thrombosis, among women with thrombophilia and oral contraceptive use: a meta-analysis. Clin Appl Thromb Hemost 2011, 17:E141-E152.
10. Blanco-Molina Á. Oral contraception in women with mild thrombophilia: what have we learned recently?. Thromb Res 2012, 130(Suppl. 1):S16-S18.
11. Wu O., Robertson L., Twaddle S., Lowe G., Clark P., Walker I., et al. Thrombosis: risk and economic assessment of thrombophilia screening (TREATS) study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005, 131:80-90.
12. Grimes D.A., Stuart G.S., Levi E.E. Screening women for oral contraception: can family history identify inherited thrombophilias?. Obstet Gynecol 2012, 20:889-895.
13. Lidegaard Ø., Løkkegaard E., Svendsen A.L., Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009, 339:b2890.
14. van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J., Rosendaal F.R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009, 339:b2921.
15. Lidegaard Ø., Nielsen L.H., Skovlund C.W., Løkkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 2012, 344:e2990.
16. Plu-Bureau G., Hugon-Rodin J., Maitrot-Mantelet L., Canonico M. Hormonal contraceptives and arterial disease: an epidemiological update. Best Pract Res Clin Endocrinol Metab 2013, 27:35-45.
17. Lidegaard Ø., Løkkegaard E., Jensen A., Skovlund C.W., Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012, 366:2257-2266.
18. Schürks M., Rist P.M., Bigal M.E., Buring J.E., Lipton R.B., Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009, 339:b3914.
19. Raps M., Helmerhorst F., Fleischer K., Thomassen S., Rosendaal F., Rosing J., et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost 2012, 10:992-997.